Trending stocks today
RepliCel Life Sciences (RP-X)
CVE:RP
0.01
Financials
Technical Analysis
Related posts
Most Anticipated Earnings: UNC-T, DAN-X and more Canadian Companies Reporting Earnings this Week (Nov 27-Dec 01)Earning Reports to Watch (Nov 26-30)
$0.440
Owned
- «
- ‹
- 1
- ›
- »
RepliCel Life Sciences(RP-X) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
RepliCel Life Sciences(RP-X) Frequently Asked Questions
What is RepliCel Life Sciences stock symbol?
RepliCel Life Sciences is a Canadian stock, trading under the symbol RP-X on the TSX Venture Exchange (RP-CV). It is usually referred to as TSXV:RP or RP-X
Is RepliCel Life Sciences a buy or a sell?
In the last year, there was no coverage of RepliCel Life Sciences published on Stockchase.
Is RepliCel Life Sciences a good investment or a top pick?
RepliCel Life Sciences was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for RepliCel Life Sciences.
Why is RepliCel Life Sciences stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is RepliCel Life Sciences worth watching?
In the last year 0 stock analysts on Stockchase covered RepliCel Life Sciences. The stock is worth watching.
What is RepliCel Life Sciences stock price?
On 2024-12-11, RepliCel Life Sciences (RP-X) stock closed at a price of $0.01.
Life sciences. Have an interesting regenerative technology. For example, they can take a hair follicle and extract certain cells, and then replicate them 1 million times and then re-inject them back in areas where they are needed. It is very, very rare to have a company this small with 2 products in phase 2 trials. Feels phase 2 is when life science companies add the most value. Next year they will have a 3rd, which is very rare for a company. Thinks they will put the company up for sale next year, and it will become a bidding war.